Q3 Earnings Estimate for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2025 earnings estimates for Nurix Therapeutics in a report issued on Monday, March 17th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.96) for the quarter. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics' Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.79) EPS and FY2026 earnings at ($3.32) EPS.

Other analysts have also recently issued reports about the stock. Stephens restated an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. JPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. BTIG Research initiated coverage on Nurix Therapeutics in a report on Tuesday, December 10th. They issued a "buy" rating and a $35.00 target price on the stock. Morgan Stanley upped their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Finally, Needham & Company LLC decreased their price target on Nurix Therapeutics from $29.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $30.88.

Remove Ads

Nurix Therapeutics Price Performance

Shares of NRIX traded up $0.35 during mid-day trading on Thursday, hitting $13.34. The company's stock had a trading volume of 976,097 shares, compared to its average volume of 870,816. The firm has a 50-day moving average price of $16.88 and a 200 day moving average price of $20.66. Nurix Therapeutics has a fifty-two week low of $11.90 and a fifty-two week high of $29.56. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -4.62 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. The trade was a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,326 shares of company stock worth $213,449 over the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NRIX. FMR LLC raised its position in shares of Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after purchasing an additional 10,047,329 shares during the period. Vanguard Group Inc. raised its holdings in Nurix Therapeutics by 8.3% in the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after acquiring an additional 333,452 shares during the period. Wellington Management Group LLP raised its holdings in Nurix Therapeutics by 3.0% in the 4th quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after acquiring an additional 104,500 shares during the period. Soleus Capital Management L.P. lifted its position in Nurix Therapeutics by 97.3% during the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock worth $39,617,000 after acquiring an additional 1,036,999 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Nurix Therapeutics by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock valued at $29,870,000 after acquiring an additional 137,087 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.